Formulation and Evaluation of Chitosan-Based Polymeric Biodegradable Mucoadhesive Buccal Delivery for Locally Acting Drugs: In Vitro, Ex Vivo and In Vivo Volunteers Characterization

Pain treatment by means of a local anesthetic and at the same time, controlling the microbial flora with an antiseptic agent can be considered as an option for delivering through mucoadhesive buccal dosage form. The objective of the current study was to develop a chitosan (CHI) based targeted polymeric buccal mucoadhesive fabrication for simultaneous release of lignocaine hydrochloride (LGN) and tibezonium iodide (TBN). Mixed ingredients were compacted via direction compression using chitosan (CHI) with sodium alginate (SA) and hypromellose (HPMC). Outcomes shown that the weight variation and friability were according to the USP specifications and were unaffected by changing amounts of the polymers in the formulations. Maximum swellability was observed in PT8, containing 7.5% of SA and CHI. Surface pH was also in accordance to the normal physiological pH range. Maximum mucoadhesive strength and time values were observed in the formulation PT4 containing 7.5% concentration of CHI and HPMC each, which were 5.76 h and 9.37 g, respectively. Same was the case for PT4 in terms of maximum simultaneous in vitro release for both drugs. The release of TBN and LGN was best fitted to Hixon Crowell release model. Formulation PT4 promised optimum results in terms of maximum release with optimum mucoadhesive values till to 4 h.